Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07262268
PHASE1

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Sponsor: Biohaven Therapeutics Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

Official title: A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2026-01-15

Completion Date

2026-11

Last Updated

2026-04-08

Healthy Volunteers

No

Interventions

DRUG

BHV-7000

Participants will take blinded investigational product (IP) orally once daily

DRUG

Placebo

Matching placebo taken orally once daily

Locations (1)

Site-001

New Haven, Connecticut, United States